Our Medicines

We are a global biopharmaceutical company focused on helping to address the unmet medical needs of patients with serious diseases. We are investing billions in Research and Development (R&D), which includes the discovery and development of new medicines.

Below is a list of our company's medicines. Any linked documents and websites are intended only for residents 18 years or older, as the availability of medicines and the indications for which they are approved can vary with country and region. 

Please refer to the patient leaflet information approved by the relevant governmental authority of the country where you are located and consult your physician for professional medical advice and services.

Pharmacovigilance Notice

Click to view notice

Healthcare professionals and patients should also report Product Quality Complaints to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

Current Products

Adcortyl Intra-Articular/Intradermal Injection 10mg/ml

Triangle Icon

Amikin Injection 100MG/2ML

Triangle Icon

Azactam 1g or 2g Powder for Solution for Injection or Infusion

Triangle Icon

Baraclude 0.05 mg/ml oral solution

Triangle Icon

Baraclude 0.5 mg and 1.0 mg film coated tablets

Triangle Icon

Daklinza ▼ 30mg and 60mg film-coated tablets 

Triangle Icon

Eliquis 2.5 mg film-coated tablets

Triangle Icon

Eliquis 5 mg film-coated tablets

Triangle Icon

Empliciti ▼ 300 mg and 400 mg powder for concentrate for solution for infusion     

Triangle Icon

Etopophos 100mg Powder for Solution for Injection

Triangle Icon

Evotaz ▼ 300 mg/150 mg film-coated tablets 

Triangle Icon

Fungizone 50mg Powder for Sterile Concentrate

Triangle Icon

Hydrea 500 mg Hard Capsules

Triangle Icon

Kenalog Intra-articular/Intramuscular Injection 40mg/ml

Triangle Icon

Nalorex 50mg Film-Coated Tablets

Triangle Icon

Nulojix 250 mg powder for concentrate for solution for infusion

Triangle Icon

Nystan 100,000 units/ml Oral Suspension (Ready-Mixed)

Triangle Icon

Opdivo ▼ 10 mg/mL concentrate for solution for infusion 

Triangle Icon

Orencia 125 mg solution for injection (pre-filled syringe)

Triangle Icon

Orencia 125 mg solution for injection (pre-filled pen)

Triangle Icon

Orencia 250 mg powder for concentrate for solution for infusion

Triangle Icon

Perfalgan 10mg/ml Solution for Infusion

Triangle Icon

Questran Light 4g/sachet Powder for Oral Suspension

Triangle Icon

Questran 4g/sachet Powder for Oral Suspension

Triangle Icon

Sotacor 80mg Tablets

Triangle Icon

Sprycel 20mg, 50mg, 80mg, 100mg and 140mg Film Coated Tablets

Triangle Icon

Sustiva 50 mg, 100 mg and 200 mg Hard Capsules

Triangle Icon

Sustiva 600 mg Film-Coated Tablets

Triangle Icon

Vepesid Soft Capsules 50 mg and 100 mg

Triangle Icon

Videx EC 125mg, 200mg, 250mg and 400mg Gastro-resistant Capsules

Triangle Icon

Yervoy 5 mg/ml concentrate for solution for infusion

Triangle Icon

Zerit 200 mg Powder for Oral Solution

Triangle Icon

Healthcare Professionals: 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com

Patients:

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects or search for MHRA Yellow Card in the Google Play or Apple App Store. Side effects should also be reported to Bristol-Myers Squibb Medical Information on 0800 731 1736 or medical.information@bms.com


Risk Minimisation

Risk Minimisation materials (e.g. educational brochures, patient alert cards, posters etc.) are intended to improve the use of a medicine by positively influencing health professionals and patients to reduce the risk and/or the severity of adverse reactions associated with a particular medicine.

These materials are additional to the medicine’s Summary of Product Characteristics (SmPC) and Patient Information Leaflet and their requirements are part of the product EU Risk Management Plan.

Only some medicines have a set of tailored risk minimisation materials developed for this purpose. If required, these materials are reviewed and approved by the Medicines and Healthcare products Regulatory Agency (MHRA).

To access risk minimisation materials (where available electronically) for our medicines, please click on the link below to the electronic Medicines Compendium (eMC) website. Please note: after clicking link below you will then need to use the medicine search function to access a medicine's risk minimisation materials. After searching by medicine, click on the "Risk Materials" tab.

When you click on the hyperlink below you will be moving away from a BMS website to a website for which BMS has no responsibility.

https://www.medicines.org.uk/emc/

If you would like a hard copy of a BMS medicine's risk minimisation materials posted out to you, please contact Bristol-Myers Squibb Medical Information (telephone: 0800 7311736, email: medical.information@bms.com) with your specific request.

 


Date of preparation: May 2018; MLTUK1701479-04